ASCO 2022 Bladder Cancer - Results from #20

Viewing 21-35 of 35 articles

ASCO 2022: Expanding Horizons in Localized Bladder Cancer

ASCO 2022: MRG002-006: A Multicenter Phase II Clinical Trial of MRG002-ADC for Unresectable Locally Advanced or Metastatic Urothelial Cancer

ASCO 2022: Final Clinical Results of Pivotal Trial of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Nonmuscle-Invasive Bladder Cancer

ASCO 2022: Results From Cohorts 3, 4, 5 of the COSMIC-021 Study - Cabozantinib in Combination With Atezolizumab in Urothelial Carcinoma

ASCO 2022: Exploratory Data From a Prospective Collection of Plasma Testing Cell-Free Methylated DNA as a Predictor of Response to Neoadjuvant Chemotherapy for Patients With Muscle-Invasive Bladder Cancer in SWOG S1314

ASCO 2022: Efficacy and Safety of Atezolizumab Concurrent with Radiotherapy in Patients with Muscle-Invasive Bladder Cancer: An Interim Analysis of the ATEZOBLADDERPRESERVE Phase II Trial (SOGUG-2017-a-IEC(VEJ)-4)

ASCO 2022: Results From the TRUCE-02 Study: Testing the Combination of Chemotherapy (Nab-Paclitaxel) With the Anti-PD-1 Antibody Tislelizumab in High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma

ASCO 2022: Cell-Free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-Invasive Bladder Cancer in SWOG S1314

ASCO 2022: Discussant: Is There a Role for VEGF-TKIs in Bladder Cancer?

ASCO 2022: Is There a Role for VEGF-TKIs in Bladder Cancer?

ASCO 2022: Final Clinical Results of Pivotal Trial of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary NMIBC

ASCO 2022: Expanding Horizons in Localized Bladder Cancer - Discussion

ASCO 2022: TRUCE-02: An Open Label, Single-Arm, Phase II Study of Tislelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma

ASCO 2022: A Randomized, Double Blind, Phase II Clinical Trial of Maintenance Cabozantinib Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Cabozantinib Comparison

ASCO 2022: Cabozantinib in Combination with Atezolizumab in Urothelial Carcinoma: Results from Cohorts 3, 4, 5 of the COSMIC-021 Study

1
2